BACKGROUND: To examine the effects of anti-VEGF antibody (bevacizumab) on the number of fenestrations in rat choriocapillaris. METHODS: Twenty-four eyes from 24 male Wister rats were injected intravitreally with 0.125 mg of bevacizumab. The rats were perfusion fixated at 1, 3, 7, 14 or 28 days after injection. The surfaces of the choriocapillaris on the RPE side were observed using scanning electron microscopy. Four eyes treated with human IgG were used as controls. The area sieve plate and the number of fenestrations after the bevacizumab injection were measured and compared with controls. RESULTS: In the controls, the sieve plate area was 80.7% of the total choriocapillaris area. The number of fenestrations was 69.2 +/- 0.2 /microm(2) of the fenestrated area. While there were no changes in the fenestrated area for any of the time points after the bevacizumab treatment, the number of fenestrations was significantly reduced to 52.9 +/- 4.4 at day 1, 55.6 +/- 3.6 at day 3 and 53.6 +/- 8.6 /microm(2) of the luminal surface at day 7 (ANOVA, p < 0.05). CONCLUSIONS: In this study, intravitreal bevacizumab injection reduced fenestration of the normal choriocapillaris. These results indicate there is a latent risk inherent with bevacizumab treatment of normal choriocapillaris.
BACKGROUND: To examine the effects of anti-VEGF antibody (bevacizumab) on the number of fenestrations in rat choriocapillaris. METHODS: Twenty-four eyes from 24 male Wister rats were injected intravitreally with 0.125 mg of bevacizumab. The rats were perfusion fixated at 1, 3, 7, 14 or 28 days after injection. The surfaces of the choriocapillaris on the RPE side were observed using scanning electron microscopy. Four eyes treated with human IgG were used as controls. The area sieve plate and the number of fenestrations after the bevacizumab injection were measured and compared with controls. RESULTS: In the controls, the sieve plate area was 80.7% of the total choriocapillaris area. The number of fenestrations was 69.2 +/- 0.2 /microm(2) of the fenestrated area. While there were no changes in the fenestrated area for any of the time points after the bevacizumab treatment, the number of fenestrations was significantly reduced to 52.9 +/- 4.4 at day 1, 55.6 +/- 3.6 at day 3 and 53.6 +/- 8.6 /microm(2) of the luminal surface at day 7 (ANOVA, p < 0.05). CONCLUSIONS: In this study, intravitreal bevacizumab injection reduced fenestration of the normal choriocapillaris. These results indicate there is a latent risk inherent with bevacizumab treatment of normal choriocapillaris.
Authors: Alexander G Marneros; Jie Fan; Yoshihito Yokoyama; Hans Peter Gerber; Napoleone Ferrara; Rosalie K Crouch; Bjorn R Olsen Journal: Am J Pathol Date: 2005-11 Impact factor: 4.307
Authors: H G Blaauwgeers; G M Holtkamp; H Rutten; A N Witmer; P Koolwijk; T A Partanen; K Alitalo; M E Kroon; A Kijlstra; V W van Hinsbergh; R O Schlingemann Journal: Am J Pathol Date: 1999-08 Impact factor: 4.307
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Felix Bock; Jasmine Onderka; Tina Dietrich; Björn Bachmann; Friedrich E Kruse; Matthias Paschke; Grit Zahn; Claus Cursiefen Journal: Invest Ophthalmol Vis Sci Date: 2007-06 Impact factor: 4.799
Authors: L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park Journal: N Engl J Med Date: 1994-12-01 Impact factor: 91.245
Authors: Ilene K Sugino; Qian Sun; Jianqiu Wang; Celia F Nunes; Noounanong Cheewatrakoolpong; Aprille Rapista; Adam C Johnson; Christopher Malcuit; Irina Klimanskaya; Robert Lanza; Marco A Zarbin Journal: Invest Ophthalmol Vis Sci Date: 2011-07-01 Impact factor: 4.799
Authors: Lindsay S Keir; Rachel Firth; Lyndsey Aponik; Daniel Feitelberg; Susumu Sakimoto; Edith Aguilar; Gavin I Welsh; Anna Richards; Yoshihiko Usui; Simon C Satchell; Valeryia Kuzmuk; Richard J Coward; Jonathan Goult; Katherine R Bull; Ruchi Sharma; Kapil Bharti; Peter D Westenskow; Iacovos P Michael; Moin A Saleem; Martin Friedlander Journal: J Clin Invest Date: 2016-12-05 Impact factor: 14.808